Oct 20

Past Event

2010 Conference on Clinical Cancer Research

Summary

On October 20, the Engelberg Center for Health Care Reform and Friends of Cancer Research hosted the 2010 Conference on Clinical Cancer Research, where key stakeholders came together to address specific challenges in clinical cancer research and discuss potential solutions proposed by expert panels.

Panelists and participants represented the range of stakeholders in the cancer community, including senior officials from the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI), as well as thought leaders from academia, patient advocacy organizations, and the life sciences industry. FDA Commissioner Dr. Margaret Hamburg and NCI Director Dr. Harold Varmus offered keynote remarks, and four panel discussions focused on:

  1. Expanding the use of adaptive clinical trial design in oncology;
  2. Innovative and efficient pre-clinical testing;
  3. Incorporating pain metrics into oncology clinical trials; and
  4. Using patient-generated data and samples to develop evidence for targeting approved treaments.

 

Details

October 20, 2010

8:30 AM - 4:30 PM EDT

Westin City Center

Ballroom

1400 M Street, NW

Map

For More Information

Engelberg Center for Health Care Reform

(202) 797-4391

Event Agenda

  • Welcome

    • mmclellanimage

      Mark B. McClellan

      Director

      Economic Studies

  • Keynote Address

    • Harold Varmus

      Director, National Cancer Institute

  • Panel 1: Expanding the Use of Adaptive Clinical Trial Design in Oncology

    • Moderator: Howard Scher

      Chief, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center

    • Raji Sridhara

      Divisions Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

    • Richard Simon

      Chief, Biometric Research Branch, National Cancer Institute

    • Eric Rubin

      Vice President, Oncology Clinical Research, Merck

    • Shelley Fuld Nasso

      Director, Public and Medical Affairs, Susan G. Komen for the Cure

  • Panel 2: Innovative and Efficient Pre-Clinical Testing

    • Moderator: Ken Turteltaub

      Executive Director, Battelle Center for Fundamental and Applied Systems Technology, Battelle Memorial Institute

    • John Leighton

      Associate Director for Pharmacology/Toxicology, U.S. Food and Drug Administration

    • Myrtle Davis

      Chief, Toxicology and Pharmacology Branch, National Cancer Institute

    • Leigh Ann Burns-Nass

      DSRD Therapeutic Area Leader-Oncology, Pfizer, Inc.

    • Adam Clark

      Director, Scientific and Federal Affairs, Faster Cures

  • Lunch and Keynote Remarks

    • Introduction: Ellen Sigal

      Friends of Cancer Research

    • Margaret Hamburg

      Commissioner, U.S. Food and Drug Administration

  • Panel 3: Incorporating Pain Metrics into Oncology Clinical Trials

    • Moderator: Charles Cleeland

      Department Chair, Department of Symptom Research, MD Anderson Cancer Center

    • Laurie Burke

      Associate Director for Study Endpoints and Labeling Development, Office of New Drugs, U.S. Food and Drug Administration

    • Ann O'Mara

      Head of Palliative Care Research, Community Oncology and Prevention Trials Research Group, National Cancer Institute

    • Martin Zagari

      Global Health Economics Head, Amgen

    • Carole Baas

      Patient Advocate

  • Panel 4: Patient Generated Samples and Data

    • Co-Moderator: Stephen Friend

      President, Sage Bionetworks

    • Co-Moderator: Richard Schilsky

      Chief-Section of Hematology-Oncology, Deputy Director, University of Chicago Comprehensive Cancer Center

    • Sue-Jane Wang

      Associate Director, Pharmacogenomics and Adaptive Design, Office of Biostatistics, U.S. Food and Drug Administration

    • Ken Buetow

      Director, Bioinformatics and Information Technology, National Cancer Institute

    • Jamie Freedman

      Executive Vice President, R&D, GlaxoSmithKline

    • Laurie Fenton Ambrose

      President, Lung Cancer Alliance

  • Summary and Closing Remarks

    • mmclellanimage

      Mark B. McClellan

      Director

      Economic Studies